Aims The advantages of direct oral anticoagulants (DOACs) over warfarin are well
established in atrial fibrillation (AF) patients, however, studies that can guide the selection …

Background: Current guidelines recommend using direct oral anticoagulants (DOACs) over
warfarin in patients with atrial fibrillation (AF), but head-to-head trial data do not exist to …

Background The comparative effectiveness and safety of individual direct oral
anticoagulants (DOACs) in clinical practice is largely unknown. The study objectives were to …

Abstract Introduction Direct oral anticoagulants (DOACs) have been proven non-inferior or
superior to warfarin in preventing stroke and systemic embolism, with a lower risk of major …

Aims To analyse the safety and efficacy of direct oral anticoagulants (DOACs) in real-world
studies including atrial fibrillation (AF) patients. Methods and results Systematic review and …

Abstract Study Objective Observational studies assessing direct oral anticoagulant (DOACs)
dosage in atrial fibrillation (AF) reported that a lower proportion of patients received high …

Aims We used the US Department of Defense Military Health System database to compare
the safety and effectiveness of direct oral anticoagulants (DOACs) in patients with non …

The study objective was to evaluate the safety and effectiveness of dabigatran and other
direct oral anticoagulants (DOACs) compared with warfarin among patients with nonvalvular …

Background We evaluated adherence to dosing criteria for patients with atrial fibrillation (AF)
taking dabigatran or rivaroxaban and the impact of off-label dosing on thromboembolic and …

Background The aim of the study was to compare the real-world effectiveness and safety in
atrial fibrillation (AF) patients treated with edoxaban versus other oral anticoagulants …